Department of Cardiology, St. Antonius Hospital, P.O. Box 2500, 3435 CM, Nieuwegein, the Netherlands,
Neth Heart J. 2011 Jun;19(6):273-8. doi: 10.1007/s12471-011-0103-7.
The objective of this study is to develop a simple risk score to predict 30-day mortality of aortic valve replacement (AVR).
In a development set of 673 consecutive patients who underwent AVR between 1990 and 1993, four independent predictors for 30-day mortality were identified: body mass index (BMI) ≥30, BMI <20, previous coronary artery bypass grafting (CABG) and recent myocardial infarction. Based on these predictors, a 30-day mortality risk score-the AVR score-was developed. The AVR score was validated on a validation set of 673 consecutive patients who underwent AVR almost two decennia later in the same hospital.
Thirty-day mortality in the development set was ≤2% in the absence of any predictor (class I, low risk), 2-5% in the solitary presence of BMI ≥30 (class II, mild risk), 5-15% in the solitary presence of previous CABG or recent myocardial infarction (class III, moderate risk), and >15% in the solitary presence of BMI <20, or any combination of BMI ≥30, previous CABG or recent myocardial infarction (class IV, high risk). The AVR score correctly predicted 30-day mortality in the validation set: observed 30-day mortality in the validation set was 2.3% in 487 class I patients, 4.4% in 137 class II patients, 13.3% in 30 class III patients and 15.8% in 19 class IV patients.
The AVR score is a simple risk score validated to predict 30-day mortality of AVR.
本研究旨在开发一种简单的风险评分,以预测主动脉瓣置换术(AVR)的 30 天死亡率。
在 1990 年至 1993 年间连续接受 AVR 的 673 例患者的发展数据集,确定了四个独立的 30 天死亡率预测因子:体重指数(BMI)≥30、BMI<20、既往冠状动脉旁路移植术(CABG)和近期心肌梗死。基于这些预测因素,开发了 30 天死亡率风险评分-AVR 评分。该 AVR 评分在同一医院近二十年后对 673 例连续接受 AVR 的验证数据集进行了验证。
在无任何预测因子的情况下,发展数据集的 30 天死亡率为≤2%(I 级,低风险),单独存在 BMI≥30 时为 2-5%(II 级,轻度风险),单独存在既往 CABG 或近期心肌梗死时为 5-15%(III 级,中度风险),且 BMI<20 时或任何 BMI≥30、既往 CABG 或近期心肌梗死的组合存在时>15%(IV 级,高风险)。AVR 评分正确预测了验证数据集的 30 天死亡率:验证数据集的观察到的 30 天死亡率在 487 例 I 级患者中为 2.3%,在 137 例 II 级患者中为 4.4%,在 30 例 III 级患者中为 13.3%,在 19 例 IV 级患者中为 15.8%。
AVR 评分是一种简单的风险评分,经验证可预测 AVR 的 30 天死亡率。